Cancer vaccine strategies get bigger and better

Tanja D. De Gruijl; David T. Curiel

doi:https://doi.org/10.1038/13443

Cancer vaccine strategies get bigger and better

Tanja D. De Gruijl, David T. Curiel

Research output: Contribution to journal › Short survey › Academic › peer-review

22 Citations (Scopus)

Abstract

Many anti-tumor vaccines have failed in recent clinical trials because they included the wrong patients and the wrong immune adjuvants - and little was learned because the anti-tumor immune response was not carefully monitored. A new tumor vaccine for lymphoma sets the stage for how future trials should be carried out (pages 1171-1177).

Original language	English
Pages (from-to)	1124-1125
Number of pages	2
Journal	Nature medicine
Volume	5
Issue number	10
DOIs	https://doi.org/10.1038/13443
Publication status	Published - 1 Oct 1999

Access to Document

https://doi.org/10.1038/13443

Cite this

@article{b92d8cc379594628a153a8e604f582dd,

title = "Cancer vaccine strategies get bigger and better",

abstract = "Many anti-tumor vaccines have failed in recent clinical trials because they included the wrong patients and the wrong immune adjuvants - and little was learned because the anti-tumor immune response was not carefully monitored. A new tumor vaccine for lymphoma sets the stage for how future trials should be carried out (pages 1171-1177).",

author = "{De Gruijl}, {Tanja D.} and Curiel, {David T.}",

year = "1999",

month = oct,

day = "1",

doi = "https://doi.org/10.1038/13443",

language = "English",

volume = "5",

pages = "1124--1125",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Cancer vaccine strategies get bigger and better

AU - De Gruijl, Tanja D.

AU - Curiel, David T.

PY - 1999/10/1

Y1 - 1999/10/1

N2 - Many anti-tumor vaccines have failed in recent clinical trials because they included the wrong patients and the wrong immune adjuvants - and little was learned because the anti-tumor immune response was not carefully monitored. A new tumor vaccine for lymphoma sets the stage for how future trials should be carried out (pages 1171-1177).

AB - Many anti-tumor vaccines have failed in recent clinical trials because they included the wrong patients and the wrong immune adjuvants - and little was learned because the anti-tumor immune response was not carefully monitored. A new tumor vaccine for lymphoma sets the stage for how future trials should be carried out (pages 1171-1177).

UR - http://www.scopus.com/inward/record.url?scp=0032825216&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/13443

DO - https://doi.org/10.1038/13443

M3 - Short survey

C2 - 10502808

SN - 1078-8956

VL - 5

SP - 1124

EP - 1125

JO - Nature medicine

JF - Nature medicine

IS - 10

ER -

Cancer vaccine strategies get bigger and better

Abstract

Access to Document

Other files and links

Cite this